ADRB2 and neoplasm: To expedite the clinical use of β-blockers in ocular diseases and tumor treatment, the intracellular signaling pathways, such as inflammatory, redox, and cell death signaling routes, modulated by activation or blockade of individual β-AR subtypes, remain to be characterized in more detail.